Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Sep 10, 2021

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 08, 2021

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

Sep 02, 2021

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

Aug 16, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Aug 11, 2021

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

Aug 10, 2021

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

Aug 10, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

Aug 10, 2021

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Aug 04, 2021

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

Jun 24, 2021

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 29

Investor Tools

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact